Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of “Moderate Buy” from Brokerages

Personalis, Inc. (NASDAQ:PSNL) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.8571.

A number of equities analysts have weighed in on the stock. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. Morgan Stanley increased their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Guggenheim boosted their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, BTIG Research lifted their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday.

Insider Activity

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in PSNL. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter worth $30,000. International Assets Investment Management LLC bought a new stake in shares of Personalis during the fourth quarter valued at about $31,000. Ameritas Investment Partners Inc. acquired a new stake in Personalis in the second quarter worth about $34,000. BNP Paribas Financial Markets grew its position in Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after buying an additional 3,592 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Stock Down 2.1%

NASDAQ:PSNL opened at $8.21 on Friday. The stock has a market cap of $729.05 million, a PE ratio of -9.33 and a beta of 1.98. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50. The firm’s fifty day simple moving average is $8.85 and its 200-day simple moving average is $7.72.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.